Eleclazine

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameEleclazine
Drug Alias Nameeleclazinum依来克秦eleclazina依克拉嗪GS-6615 +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSodium channel protein type V alpha subunit blockers
TargetsSodium channel protein type V alpha subunit
Therapy Area/IndicationsMyocardial IschemiaCardiomyopathy, HypertrophicLong QT Syndrome +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaCanadaUnited States +[16] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGilead Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGilead Sciences Inc
Active IndicationsN/A
Inactive IndicationsMyocardial IschemiaCardiomyopathy, HypertrophicLong QT Syndrome +[4] 

Other Information

ATC CodeN/A
Related LinksN/A